U.S. patent application number 17/150230 was filed with the patent office on 2021-12-09 for potassium channel modulators.
The applicant listed for this patent is Cadent Therapeutics, Inc.. Invention is credited to Dipak Vasantrao Amrutkar, Kelly Foster, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, Karin Sandager Nielsen.
Application Number | 20210380571 17/150230 |
Document ID | / |
Family ID | 1000005784835 |
Filed Date | 2021-12-09 |
United States Patent
Application |
20210380571 |
Kind Code |
A1 |
Amrutkar; Dipak Vasantrao ;
et al. |
December 9, 2021 |
POTASSIUM CHANNEL MODULATORS
Abstract
Provided are compounds and pharmaceutically acceptable salts
thereof, which are useful for treating a variety of diseases,
disorders or conditions, associated with potassium channels.
Inventors: |
Amrutkar; Dipak Vasantrao;
(Ballerup, DK) ; Foster; Kelly; (Watertown,
MA) ; Jacobsen; Thomas Amos; (Oested, DK) ;
Jefson; Martin R.; (Stonington, CT) ; Keaney; Gregg
F.; (Lexington, MA) ; Larsen; Janus Schreiber;
(Holb.ae butted.k, DK) ; Nielsen; Karin Sandager;
(Fredensborg, DK) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Cadent Therapeutics, Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
1000005784835 |
Appl. No.: |
17/150230 |
Filed: |
January 15, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16897743 |
Jun 10, 2020 |
|
|
|
17150230 |
|
|
|
|
16431212 |
Jun 4, 2019 |
10717728 |
|
|
16897743 |
|
|
|
|
15938292 |
Mar 28, 2018 |
10351553 |
|
|
16431212 |
|
|
|
|
15877910 |
Jan 23, 2018 |
9975886 |
|
|
15938292 |
|
|
|
|
62449270 |
Jan 23, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 417/04 20130101;
A61K 31/5355 20130101; C07D 403/04 20130101; A61P 25/30 20180101;
C07D 413/14 20130101 |
International
Class: |
C07D 413/14 20060101
C07D413/14; A61K 31/5355 20060101 A61K031/5355; C07D 403/04
20060101 C07D403/04; C07D 417/04 20060101 C07D417/04; A61P 25/30
20060101 A61P025/30 |
Claims
1. A compound of the formula: ##STR00037## ##STR00038## or a
pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound of claim 1,
or a pharmaceutically acceptable salt thereof; and a
pharmaceutically acceptable carrier.
3. A method of treating a disease or condition responsive to
modulation of the small conductance calcium-activated potassium
channel (SK channel) in a subject in need thereof comprising the
step of administering a compound of claim 1 to the subject, or a
pharmaceutically acceptable salt thereof, or the composition of
claim 2.
4. The method of claim 3, wherein the disease or condition is
response to the modulation of the SK2 channel.
5. The method of claim 3, wherein the disease or condition is
selected from a neurodegenerative disease, dementia, heart disease,
withdrawal symptoms associated with termination of addiction,
metabolic disease, and bladder disease.
6. The method of claim 3, wherein the disease or condition is
selected from ataxia, dystonia, tremors, Parkinson's disease,
ischemia, traumatic brain injury, amyotrophic lateral sclerosis,
hypertension, atherosclerosis, diabetes, arrhythmia, over-active
bladder, and withdrawal symptoms caused by the termination of abuse
of alcohol and other drugs of abuse.
7. The method of claim 6, wherein the disease or condition is
essential tremor.
8. The method of claim 6, wherein the disease or condition is
ataxia.
9. The method of claim 8, wherein the disease or condition is
spinocerebellar ataxia.
Description
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 62/449,270, filed Jan. 23, 2017, the entire
contents of which are incorporated herein by reference.
BACKGROUND
[0002] Among the ion channels, potassium channels are the most
prevalent and diverse, being found in a variety of animal cells
such as nervous, muscular, glandular, immune, reproductive, and
epithelial tissue. These channels allow the flow of potassium in
and/or out of the cell under certain conditions. These channels are
regulated, e.g., by calcium sensitivity, voltage-gating, second
messengers, extracellular ligands, and ATP-sensitivity.
[0003] Dysfunction of potassium channels and dysfunction from other
causes which influence these potassium channels are known to
generate loss of cellular control, altered physiological function,
and disease conditions. Because of their ability to modulate ion
channel function and/or regain ion channel activity, potassium
channel modulators are being used in the pharmacological treatment
of a wide range of pathological diseases and have the potential to
address an even wider variety of therapeutic indications.
[0004] The small conductance calcium-activated potassium channels
(SK channel) are a subfamily of Ca.sup.2+-activated K.sup.+
channels and the SK channel family contains 4 members--SK1, SK2,
SK3, and SK4 (often referred to as intermediate conductance). The
physiological roles of the SK channels have been especially studied
in the nervous system, where for example they are key regulators of
neuronal excitability and of neurotransmitter release, and in
smooth muscle, where they are crucial in modulating the tone of
vascular, broncho-tracheal, urethral, uterine or gastro-intestinal
musculature.
[0005] Given these implications, small molecule modulators of
potassium ion channels could have the potential to treat a large
variety of diseases characterized by dysfunction of potassium ion
channels and dysfunction from other causes which influence these
potassium channels.
SUMMARY
[0006] Disclosed are compounds and pharmaceutically acceptable
salts thereof, and pharmaceutical compositions thereof, which are
useful in the treatment of diseases associated with the dysfunction
of potassium ion channels and dysfunction from other causes which
influence these potassium channels. (See e.g., Table 1).
[0007] The compounds described herein were found to have one or
more of the following beneficial properties: high solubility, high
brain free fraction, little or no hERG inhibition, extended in vivo
half-lives, good bioavailability, high liver microsomal stability,
enhanced permeability such as parallel artificial membrane
permeability (PAMPA), and/or low Cyp inhibition. See e.g., the
comparative data in Tables 2 and 3.
BRIEF DESCRIPTION OF THE FIGURES
[0008] FIG. 1 is a diagram illustrating the effect of Compound 1
following oral (PO) dosing on harmaline induced tremor.
[0009] FIG. 2 displays the efficacy and dose response of Compound 1
in percent motion power.
[0010] FIG. 3 shows the effects of Compound 1 on Purkinje cell
firing irregularity in ex vivo slices from SCA2 58Q transgenic
mice.
[0011] FIG. 4 shows the effects of Compound 1 on baseline ataxia in
the EA2 Tottering mouse model.
DETAILED DESCRIPTION
1. Compounds
[0012] Provided herein are compounds of the formula:
##STR00001## ##STR00002##
or pharmaceutically acceptable salts thereof.
2. Definitions
[0013] As used herein the terms "subject" and "patient" may be used
interchangeably, and means a mammal in need of treatment, e.g.,
companion animals (e.g., dogs, cats, and the like), farm animals
(e.g., cows, pigs, horses, sheep, goats and the like) and
laboratory animals (e.g., rats, mice, guinea pigs and the like).
Typically, the subject is a human in need of treatment.
[0014] When the stereochemistry of a disclosed compound is named or
depicted by structure, the named or depicted stereoisomer is at
least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to
all of the other stereoisomers. Percent by weight pure relative to
all of the other stereoisomers is the ratio of the weight of one
stereoisiomer over the weight of the other stereoisomers. When a
single enantiomer is named or depicted by structure, the depicted
or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by
weight optically pure. Percent optical purity by weight is the
ratio of the weight of the enantiomer over the weight of the
enantiomer plus the weight of its optical isomer.
[0015] When a disclosed compound is named or depicted by structure
without indicating the stereochemistry, and the compound has one
chiral center, it is to be understood that the name or structure
encompasses one enantiomer of compound free from the corresponding
optical and geometric isomer, a racemic mixture of the compound,
and mixtures enriched in one enantiomer relative to its
corresponding optical isomer.
[0016] Pharmaceutically acceptable salts as well as the neutral
forms of the compounds described herein are included. For use in
medicines, the salts of the compounds refer to non-toxic
"pharmaceutically acceptable salts." Pharmaceutically acceptable
salt forms include pharmaceutically acceptable acidic/anionic or
basic/cationic salts. Pharmaceutically acceptable basic/cationic
salts include, the sodium, potassium, calcium, magnesium,
diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine,
ammonium, ethanolamine, piperazine and triethanolamine salts.
Pharmaceutically acceptable acidic/anionic salts include, e.g., the
acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate,
carbonate, citrate, dihydrochloride, gluconate, glutamate,
glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride,
malate, maleate, malonate, mesylate, nitrate, salicylate, stearate,
succinate, sulfate, tartrate, and tosylate.
[0017] The term "pharmaceutically acceptable carrier, adjuvant, or
vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that
does not destroy the pharmacological activity of the compound with
which it is formulated. Pharmaceutically acceptable carriers,
adjuvants or vehicles that may be used in the compositions
described herein include, but are not limited to, ion exchangers,
alumina, aluminum stearate, lecithin, serum proteins, such as human
serum albumin, buffer substances such as phosphates, glycine,
sorbic acid, potassium sorbate, partial glyceride mixtures of
saturated vegetable fatty acids, water, salts or electrolytes, such
as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
substances, polyethylene glycol, sodium carboxymethylcellulose,
polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,
polyethylene glycol and wool fat.
[0018] The terms "treatment," "treat," and "treating" refer to
reversing, alleviating, reducing the likelihood of developing, or
inhibiting the progress of a disease or disorder, or one or more
symptoms thereof, as described herein. In some embodiments,
treatment may be administered after one or more symptoms have
developed, i.e., therapeutic treatment. In other embodiments,
treatment may be administered in the absence of symptoms. For
example, treatment may be administered to a susceptible individual
prior to the onset of symptoms (e.g., in light of a history of
symptoms and/or in light of genetic or other susceptibility
factors), i.e., prophylactic treatment. Treatment may also be
continued after symptoms have resolved, for example to prevent or
delay their recurrence.
[0019] The term "effective amount" or "therapeutically effective
amount" includes an amount of a compound described herein that will
elicit a biological or medical response of a subject.
3. Uses, Formulation and Administration
[0020] In some embodiments, compounds and compositions described
herein are useful in treating diseases and/or disorders associated
with the activity of potassium channels. Such diseases and/or
disorders include e.g., neurodegenerative and neurological
conditions (e.g., Parkinson's disease, tremors, Alzheimer's
disease, dementia, amyotrophic lateral sclerosis (ALS) ataxia,
anxiety, depression, mood disorders, memory and attention deficits,
bipolar disorder, psychosis, schizophrenia, traumatic brain injury,
and narcolepsy), heart disease and related conditions (e.g.,
ischaemic heart disease, coronary heart disease, angina pectoris,
and coronary artery spasms), metabolic disease and bladder diseases
(e.g., bladder spasms, urinary incontinence, bladder outflow
obstruction, gastrointestinal dysfunction, irritable bowel
syndrome, and diabetes), withdrawal symptoms associated with
termination of addiction, and other conditions associated with the
modulation of potassium channels such as e.g., respiratory
diseases, epilepsy, convulsions, seizures, absence seizures,
vascular spasms, renal disorders (e.g., polycystic kidney disease),
erectile dysfunction, secretory diarrhoea, ischaemia, cerebral
ischaemia, dysmenorrhea, Reynaud's disease, intermittent
claudication, Sjorgren's syndrome, arrhythmia, hypertension,
myotonic muscle dystrophia, spasticity, xerostomi,
hyperinsulinemia, premature labor, baldness, cancer, immune
suppression, migraine and pain.
[0021] The present disclosure also provides a method of modulating
the activity of a potassium channel in a subject comprising the
step of administering a compound described herein. In another
embodiment, the present disclosure provides a method of positively
modulating a SK2 channel in a cell comprising the step of
contacting the cell with a compound described herein.
[0022] In one aspect, the provided compounds and compositions are
used to treat tremors. Tremors include, but are not limited to
rest, active, postural, kinetic, intention, task specific, and
idiopathic tremors. In one aspect, the provided compounds and
compositions are used to treat postural and active tremors.
Examples of postural and/or active tremors include essential
tremor, drug-induced parkinsonism, neuropathic tremor, and tremors
induced from toxins (e.g., alcohol withdrawal or from exposure to
heavy metals). In one aspect, the provided compounds and
compositions are used to treat essential tremor.
[0023] The present disclosure further provides a method of treating
essential tremor in a subject comprising the step of administering
a compound or pharmaceutically acceptable salt or composition
described herein.
[0024] Essential tremor is one of the most common neurological
disorders, affecting .about.0.9% of the general population.
Essential tremor is characterized by an action tremor of the upper
limbs and, less commonly, the head, voice, and trunk. A family
history of essential tremor can be identified in approximately half
of patients, suggesting a genetic component. Drinking alcohol often
temporarily reduces tremor.
[0025] In some embodiments, the present disclosure provides a
method of treating a disease or condition selected from a
neurodegenerative disease, dementia, heart disease, withdrawal
symptoms associated with termination of addiction, metabolic
disease, and bladder disease. In other embodiments, the present
disclosure provides a method of treating a disease or condition
selected from ataxia, dystonia, Parkinson's disease, ischemia,
traumatic brain injury, amyotrophic lateral sclerosis,
hypertension, atherosclerosis, diabetes, arrhythmia, over-active
bladder, and withdrawal symptoms caused by the termination of abuse
of alcohol and other drugs of abuse. In some embodiments, the
present disclosure provides a method of treating ataxia. In some
embodiments, the present disclosure provides a method of treating
spinocerebellar ataxia.
[0026] The present disclosure provides pharmaceutically acceptable
compositions comprising a compound described herein; and a
pharmaceutically acceptable carrier. These compositions can be used
to treat one or more of the diseases and conditions described
above.
[0027] Compositions described herein may be administered orally,
parenterally, by inhalation spray, topically, rectally, nasally,
buccally, vaginally or via an implanted reservoir. The term
"parenteral" as used herein includes subcutaneous, intravenous,
intramuscular, intra-articular, intra-synovial, intrasternal,
intrathecal, intrahepatic, intralesional and intracranial injection
or infusion techniques. Liquid dosage forms, injectable
preparations, solid dispersion forms, and dosage forms for topical
or transdermal administration of a compound are included
herein.
[0028] The amount of provided compounds that may be combined with
carrier materials to produce a composition in a single dosage form
will vary depending upon the patient to be treated and the
particular mode of administration. In some embodiments, provided
compositions may be formulated so that a dosage of between 0.01-100
mg/kg body weight/day of the provided compound, such as e.g.,
0.1-100 mg/kg body weight/day, can be administered to a patient
receiving these compositions.
[0029] It should also be understood that a specific dosage and
treatment regimen for any particular patient will depend upon a
variety of factors, including age, body weight, general health,
sex, diet, time of administration, rate of excretion, drug
combination, the judgment of the treating physician, and the
severity of the particular disease being treated. The amount of a
provided compound in the composition will also depend upon the
particular compound in the composition.
Exemplification
[0030] The representative examples that follow are intended to help
illustrate the present disclosure, and are not intended to, nor
should they be construed to, limit the scope of the invention.
N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimi-
din-4-amine
[0031] Step 1:
##STR00003##
[0032] A round-bottomed flask equipped with a teflon-coated stir
bar was charged with 4,6-dichloro-2-(methylsulfonyl)pyrimidine
(20.0 g, 88.080 mmol, 1.0 eq) in tetrahydrofuran at -10.degree. C.
and 3-methyl-1H-pyrazole (7.23 g, 88.080 mmol, 1.0 equiv.) was
added dropwise over a period of five minutes via syringe. The
reaction mixture was stirred for 16 hours at 25.degree. C. and
completion of reaction was determined by TLC. The reaction mixture
was portioned between water (500 mL) and ethyl acetate (500 mL).
The organic layer was separated and the aqueous layer was extracted
with ethyl acetate (2*100 mL). The combined organic layer was dried
over sodium sulfate, filtered, and concentrated under reduced
pressure to afford crude product which was purified by column
chromatography (ethyl acetate/hexane as solvent system) to afford
4,6-dichloro-2-(3-methyl-1H-pyrazol-1-yl)pyrimidine (10.0 g, 43.859
mmol, 50% yield) as a white solid pure form. MS (MH+):
m/z=229.1.
[0033] Step 2:
##STR00004##
[0034] A round-bottomed flask equipped with a teflon-coated stir
bar was charged with 2,4-dichloro-6-methylpyrimidine (11.0 g, 48.24
mmol, 1.0 equiv.), 4,4-difluorocyclohexan-1-amine hydrochloride
(9.89 g, 57.89 mmol, 1.2 equiv.), and Cs.sub.2CO.sub.3 (39.19 g,
120.61 mmol, 2.5 equiv.) in acetonitrile (200 mL). The reaction
mixture was stirred for five hours at 80.degree. C. and the
completion of reaction was determined by TLC. The reaction mixture
was cooled to room temperature and partitioned between water (100
mL) and ethyl acetate (200 mL). The organic layer was separated and
the aqueous layer was extracted ethyl acetate (2.times.100 mL). The
combined organic layer was dried over sodium sulfate, filtered, and
concentrated under reduced pressure to afford crude product which
was purified by column chromatography (ethyl acetate/hexane as
solvent system) to afford
6-chloro-N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)pyrimidin-
-4-amine (11.0 g, 33.62 mmol, 71%) as an off-white solid. MS (MH+):
m/z=328.1.
[0035] Step 3:
##STR00005##
[0036] A round-bottomed flask equipped with a teflon-coated stir
bar was charged with
6-chloro-N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)pyrimidin-
-4-amine (14.0 g, 42.79 mmol, 1.0 eq), morpholine (14.91 mL, 171.19
mmol, 4.0 eq), and triethylamine (23.89 mL, 171.19 mmol, 4.0 eq) in
acetonitrile (200 mL). The reaction mixture was stirred for 16
hours at 80.degree. C. and completion of reaction was determined by
TLC. The reaction mixture was cooled to room temperature and
partitioned between water (100 mL) and ethyl acetate (300 mL). The
organic layer was separated and the aqueous layer was extracted
ethyl acetate (2.times.100 mL). The combined organic layer was
dried over sodium sulfate, filtered, and concentrated under reduced
pressure to afford crude product which was purified by column
chromatography (ethyl acetate/hexane as solvent system) to afford
N-(4,4-difluorocyclohexyl)-2-(3
-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amine (1) (12.8 g,
33.84 mmol, 79% yield) as an off-white solid.
[0037] Analytical Data:
[0038] MS (MH.sup.+): m/z=379.2; .sup.1H NMR (400 MHz, DMSO-D6):
.delta. 8.41 (d, J=2 Hz, 1H), 7.07 (d, J=8.3 Hz, 1H), 6.25 (d,
J=2.4 Hz, 1H), 5.53 (s, 1H), 3.9 (bs, 1H), 3.67 (t, J=4.4 Hz, 4H),
3.49 (S, 4H), 2.23 (s, 3 H), 2.23-1.97 (m, 3H), 1.92-1.90 (m, 3H),
1.55-1.53 (m, 2H). .sup.1H NMR exhibited, via integration, 3 proton
resonances in the aromatic region and 1 broad resonance
corresponding to the exchangeable proton at N-18. The aromatic
protons were observed as two doublets and a singlet, indicating two
adjacent protons, and one isolated aromatic proton. In the
aliphatic region, resonances corresponding to 20 protons were
observed, showing 1 distinct singlet. Integration of these
resonances corresponded to two upfield doublet-doublet resonances,
one with a partially overlapping multiplet proton, and four
downfield multiplets, two of which partially overlap. The upfield
aliphatic multiplets are associated with the morpholine moiety of
the structure. The downfield multiplets are split additionally by
the proximity of CF.sub.2 to these protons. In the high resolution
(HR) LC/MS analysis, the pseudomolecular ion (M+H.sup.+) was
observed at low fragmentor voltage (70V) in ESI positive ion mode
at m/z 379.20580. The other prominent ion observed at m/z 779.38575
is attributable to the in-source dimer adduct 2M+Na.sup.+.
[0039] .sup.13C NMR data revealed 14 separate carbon resonances and
were generated from a decoupled .sup.13C carbon spectrum acquired
at 25.degree. C. in CDCl.sub.3. The 14 resonances are consistent
with the structure of 1 in which four pairs of the 18 carbons are
spectroscopically equivalent. One carbon resonance (C-12 at 77.05
ppm) was observed to be partially obscured by the CHCl.sub.3
resonance in the spectrum. The presence of a carbon at this
resonance was confirmed by collection of a .sup.13C spectrum in
C.sub.6D.sub.6; a resonance at 79.7 ppm was observed without
interference from the solvent peak, in addition to all other
resonances observed. A triplet (2J=244 Hz) is observed at the C-22
resonance of 122.29, two additional triplets are observed at 31.53
ppm (C-21 & C-23, 3J=24.93 Hz), and at 31.53 ppm (C-20 &
C-24, 4J=5.37 Hz). Each of the triplets observed are consistent
with F2 substitution at C-22, and decreasing coupling constant with
respect to fluorine as the number of intervening bonds
increase.
[0040] Carbon-proton connectivity, and carbon-carbon connectivity
(via 2 and 3-bond C-C-H correlations) of the molecular framework
was confirmed by the collection of 2D NMR spectra. Direct C-H
connectivity was confirmed by HSQC, and 2- and 3-bond connectivity
was demonstrated by HMBC. The short- and long-range cross
correlations (over 2 or 3 bonds) are consistent with the
connections expected from the proposed structure. Finally, observed
chemical shift data assigned as shown above was consistent with
computer-predicted .sup.1H and .sup.13C chemical shifts for the
proposed structure.
N-(4,4-difluorocyclohexyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methoxypyrim-
idin-4-amine
[0041] Step 1:
##STR00006##
[0042] A 5000-mL four-necked, flame-dried, round-bottomed flask,
equipped with a teflon-coated stir blade (5 cm) attached with glass
rod (neck 1), stopper (neck 2), and addition funnel with stopper
(neck 3) and a nitrogen gas inlet-outlet U-tube adaptor filled with
oil (Neck 4), was charged with a suspension of sodium hydride (35.2
g, 880 mmol, 1 equiv.) in dichloromethane (1000 mL) was added
3,5-dimethylpyrazole (84.6 g, 880 mmol, 1 equiv.) at 0.degree. C.
and the reaction mixture was stirred at room temperature. After 30
min, 4,6-dichloro-2-(methylsulfonyl)pyrimidine (200 g, 880 mmol, 1
equiv.) (dissolved in dichloromethane (1000 mL)) was added dropwise
through dropping funnel to the reaction mixture at -78.degree. C.
The reaction mixture was stirred at same temperature and the
completion of reaction was determined by TLC and UPLC. After 2 h,
the reaction mixture was quenched with water at -78.degree. C. and
diluted with dichloromethane. After 5 min, dichloromethane was
decanted and washed with brine solution. The organic layer was
dried over sodium sulfate, filtered, and concentrated under reduced
pressure to afford crude product, which was purified by column
chromatography using ethyl acetate and pet-ether as solvent to
afford 4,6-dichloro-2-(3, 5-dimethyl-1 h-pyrazol-1-yl) pyrimidine
(138 g, 567.71 mmol, 65%) as an off-white solid. MS (MH+):
m/z=244.2.
[0043] Step 2:
##STR00007##
[0044] A 2000-mL three-necked, flame-dried, round-bottomed flask,
equipped with a teflon-coated stir bar (5 cm), one septa (neck 1),
stopper (neck 3) and reflux condenser equipped with nitrogen gas
inlet-outlet U-tube adaptor filled with oil (Neck 2), was charged
with a solution of 4,6-dichloro-2-(3,5-dimethyl-1h-pyrazol-1-yl)
pyrimidine (136 g, 559.4 mmol, 1 equiv.) in acetonitrile (1500 mL)
followed by 4,4-difluorocyclohexylamine hydrochloride (105.6 g,
615.4 mmol, 1.1 equiv.) and N,N-diisopropyl ethylamine (194.88 mL,
1118.8 mmol, 2 equiv). The reaction mixture was heated at
80.degree. C. for 16 h. The completion of reaction was determined
by TLC and UPLC. The reaction mixture was concentrated and the
residue was triturated with water (500 mL). The resulting solid was
filtered, washed with pet-ether, dried under vacuum to afford
6-chloro-N-(4,4-difluorocyclohexyl)-2-(3,5-dimethyl-1h-pyrazol--
1-yl)pyrimidin-4-amine (191 g, 556 mmol, >95%) as an off-white
solid. MS (MH+): m/z=342.0.
[0045] Step 3:
##STR00008##
[0046] A 250 mL three-necked, flame-dried, round-bottomed flask,
equipped with a teflon-coated stir bar (2 cm), one septa (neck 1),
stopper (neck 3) and reflux condenser equipped with nitrogen gas
inlet-outlet U-tube adaptor filled with oil (Neck 2), was charged
with a solution of
6-chloro-N-(4,4-difluorocyclohexyl)-2-(3,5-dimethyl-lh-pyrazol-1-yl)pyrim-
idin-4-amine (20 g, 58.51 mmol, 1 equiv.) in methanol followed by
sodium methoxide (21% in methanol, 5.37 g, 99.47 mmol, 1.7 equiv.).
The reaction was heated to 60.degree. C., and completion of
reaction was determined by TLC and UPLC. After 5 h, the reaction
mixture was concentrated under reduced pressure and the residue was
diluted with ethyl acetate, washed with water, and washed with
brine solution. The organic layer was dried over sodium sulfate,
filtered, and concentrated under reduced pressure to afford the
crude product which was purified by column chromatography using
ethyl acetate in pet-ether as solvent system to afford
N-(4,4-difluorocyclohexyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methoxypyri-
midin-4-amine (2) [16 g (11 g (99% pure)+5 g (92% pure), 47.41
mmol, .about.80%) as a white solid. MS (MH+): m/z=338.1. Analytical
Data: .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 7.45 (bs, 1H),
6.06 (s, 1H), 5.72 (s, 1H), 4.01 (bs, 1H), 3.85 (s, 3H), 2.55 (s,
3H), 2.17 (s, 3H), 2.11-1.82 (m, 6H), 1.60-1.55 (m, 2H).
N-(4, 4-difluorocyclohexyl)-6-methoxy-2-(4-methylthiazol-2-yl)
pyrimidin-4-amine
[0047] Step 1:
##STR00009##
[0048] A three-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with diethyl ether (250 mL) and
n-BuLi (241.98 mL, 604.96 mmol, 2.5M in hexane) was transferred at
-78.degree. C. A solution of 4-methylthiazole (50.0 g, 504.13 mmol)
in diethyl ether (200 mL) was added over a period of 30 min. The
reaction mixture was turned into pale yellow suspension. After 1.5
hours, DMF (58.54 mL, 756.20 mmol) was added and stirred at room
temperature for 16 h. The progress of the reaction was monitored by
TLC. After completion of the reaction, the mixture was poured into
cold aq. HCl (400 mL, 4N) under stirring and separated the two
layers. The organic layer was washed with cold aq. HCl (2.times.80
mL, 4N)). The combined aq. layers were slowly basified with
K.sub.2CO.sub.3 (pH 7) and extracted with diethyl ether
(3.times.150 mL). The combined organic layers were dried over
sodium sulfate and evaporated to dryness at room temperature under
vacuum to afford 4-methylthiazole-2-carbaldehyde (60.0 g, crude) as
a pale yellow liquid. This crude material was used in the next step
without further purification.
[0049] Step 2:
##STR00010##
[0050] A two-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with
4-methylthiazole-2-carbaldehyde (60.0 g, crude) in pyridine (38.04
ml, 472.40 mmol). Hydroxylamine hydrochloride (32.82 g, 472.40
mmol) was added in portions over a period of 15 min. The reaction
mixture was stirred at room temperature for 16 h under nitrogen
atmosphere. The progress of the reaction was monitored by TLC.
After completion of the reaction, the mixture was poured into ice
cold water and stirred for 20 min, the obtained solid was filtered
and dried under vacuum to afford 4-methylthiazole-2-carbaldehyde
oxime (40.0 g, 281.69 mmol, 59% for two steps) as an off white
solid. MS (MH+): m/z=143.0.
[0051] Step 3:
##STR00011##
[0052] A two-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with a solution of
4-methylthiazole-2-carbaldehyde oxime (35.0 g, 246.44 mmol) and
pyridine (87.33 mL, 1084.35 mmol) in 1, 4-dioxane (140 mL).
Trifluoroacetic anhydride (51.38 mL, 369.66 mmol) was added slowly
at -10.degree. C. and allowed to stir at room temperature for 16 h.
The progress of the reaction was monitored by TLC. After completion
of the reaction, the mixture was diluted with water (250 mL) and
extracted with diethyl ether (3.times.350 mL). The combined organic
layers were washed with water (2.times.250 mL), brine (100 mL)
dried over sodium sulphate and concentrated under reduced pressure
to afford 4-methylthiazole-2-carbonitrile (35.0 g, crude) as light
brown liquid. This crude material was used in the next step without
further purification. Analytical Data: .sup.H-NMR (400 MHz,
DMSO-d.sub.6): .delta. 6 7.90 (s, 1 H), 2.51 (s, 3 H).
[0053] Step 4:
##STR00012##
[0054] A two-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with
4-methylthiazole-2-carbonitrile (35.0 g, crude) in methanol (280
mL) and sodium methoxide (16.77 g, 310.45 mmol) was added. After
stirring at room temperature for 3 h, ammonium chloride (30.19 g,
564.66 mmol) was added and stirred for another 16 h. The progress
of the reaction was monitored by TLC. After completion of the
reaction, the mixture was filtered and washed with methanol. The
filtrate was concentrated under reduced pressure and the residue
was triturated with diethyl ether (150 mL). The formed solid was
filtered and dried under vacuum to afford
4-methylthiazole-2-carboximidamide hydrochloride (35.0 g, crude) as
an off-white solid. This crude material was used in the next step
without further purification. MS (MH+): m/z=142.0.
[0055] Step 5:
##STR00013##
[0056] A two-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with
4-methylthiazole-2-carboximidamide hydrochloride (35.0 g, crude) in
ethanol (350 mL) and diethyl malonate (150.81 mL, 988.64 mmol).
Sodium ethoxide (320 mL, 988.64 mmol, 21% in EtOH) was added
dropwise at room temperature and heated to 85.degree. C. After 3
hours, the reaction mixture was concentrated under reduced
pressure. Water (20 mL) was added and acidified with 1.5 N HCl (pH
2-3). The obtained solid was filtered and dried under vacuum to
afford 2-(4-methylthiazol-2-yl) pyrimidine-4, 6-diol (29.0 g,
crude) as pale yellow solid. This crude material was used in the
next step without further purification. MS (MH+): m/z=210.
[0057] Step 6:
##STR00014##
[0058] A two-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with a suspension of
2-(4-methylthiazol-2-yl) pyrimidine-4, 6-diol (29.0 g, crude) and
POCl.sub.3 (290 mL). N,N-diethylaniline (37.84 mL, 235.85 mmol) was
added at room temperature and heated reflux at 100.degree. C. for 2
h. The progress of the reaction was monitored by TLC. Excess
POCl.sub.3 was removed by distillation. The residue was diluted
with 500 mL cold water, neutralized with saturated sodium
bicarbonate solution, extracted with diethyl ether (2.times.500
mL). The combined organic layers were washed with water
(3.times.200 mL), brine (100 mL), dried over sodium sulfate and
concentrated under reduced pressure. The residue was triturated
with n-pentane (100 mL). The obtained solid was filtered and dried
under vacuum to afford 2-(4,
6-dichloropyrimidin-2-yl)-4-methylthiazole 7 (19.5 g, 79.59 mmol,
32% for four steps) as a pale yellow solid. MS (MH+):
m/z=245.9.
[0059] Step 7:
##STR00015##
[0060] A two necked round bottomed flask equipped with a
teflon-coated stir bar was charged with a suspension of
2-(4,6-dichloropyrimidin-2-yl)-4-methylthiazole (19.0 g, 77.56
mmol) and 4, 4-difluorocyclohexan-l-amine hydrochloride (13.30 g,
77.56 mmol) in acetonitrile (190 mL). Cesium carbonate (37.89 g,
116.34 mmol) was added and the reaction mixture was heated at
80.degree. C. for 16 h. The progress of the reaction was monitored
by TLC. The reaction mixture was cooled to room temperature,
filtered, and the solid was washed with ethyl acetate (500 mL). The
filtrate was washed with water (2.times.100 mL), brine (100 mL),
dried over sodium sulfate, and concentrated under reduced pressure.
The residue was purified by column chromatography (60-120 silica
gel) eluted with 15% EtOAc in hexane. Relevant fractions containing
the required compound were combined and evaporated to dryness under
reduced pressure to afford
6-chloro-N-(4,4-difluorocyclohexyl)-2-(4-methylthiazol-2-yl)pyrimidin-4-a-
mine (22.5 g, 65.25 mmol, 84%) as off-white foam solid. MS (MH+):
m/z=344.9.
[0061] Step 8:
##STR00016##
[0062] A two-necked round bottomed flask equipped with a
teflon-coated stir bar was charged with 6-chloro-N-(4,
4-difluorocyclohexyl)-2-(4-methylthiazol-2-yl) pyrimidin-4-amine
(27.0 g, 78.47 mmol) in methanol (450 mL). Sodium methoxide (21.19
g, 392.36 mmol) was added and heated to 80.degree. C. for 16 h. The
progress of the reaction was monitored by TLC. Excess methanol was
removed under reduced pressure and the residue was diluted with 10%
aqueous ammonium chloride solution (100 mL) and extracted with
ethyl acetate (3.times.150 mL). The combined organic layers were
washed with water (2.times.100 mL), brine (100 mL), dried over
sodium sulphate and concentrated under reduced pressure. The
residue was purified by column chromatography (60-120 silica gel)
eluting with 35-40% of EtOAc in hexane. Relevant fractions
containing the target compound were combined and evaporated to
dryness under reduced pressure to afford N-(4,
4-difluorocyclohexyl)-6-methoxy-2-(4-methylthiazol-2-yl)
pyrimidin-4-amine (3) (23.4 g, 68.82 mmol, 87%) as an off-white
solid. MS (MH+): m/z=341.0. Analytical Data: .sup.1H-NMR (400 MHz,
DMSO-d.sub.6): .delta. 7.41 (s, 1 H), 7.40 (s, 1 H), 5.81 (s, 1 H),
3.87 (s, 3 H), 2.43 (s, 3 H), 2.08-1.89 (m, 6 H), 1.61-1.52 (m,
2H).
(S)-1-(6-((4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidin-
-4-yl)ethan-1-ol
[0063] Step 1:
##STR00017##
[0064] A 250-mL sealed tube, equipped with a teflon-coated stir bar
(2 cm), was charged with a solution of
6-chloro-N-(4,4-difluorocyclohexyl)-2-(4-methylthiazol-2-yl)pyrimidin-4-a-
mine (4.9 g, 14.24 mmol, 1.0 eq) and
tributyl(1-ethoxyvinyl)stannane (5.65 g, 15.66 mmol, 1.1 eq) in
N,N-dimethylformamide (60 mL). The reaction mixture was degassed
using argon gas for 5-10 min, followed by addition of
bis(triphenylphosphine)palladium(II) dichloride (0.2 g, 0.28 mmol,
0.02 eq). The reaction mixture was sealed and heated at 80.degree.
C. for 16 h (completion of reaction was determined by LCMS) and
cooled to room temperature. The reaction mixture was diluted with
water (300 mL) and extracted with ethyl acetate (2.times.150 mL).
The combined organics were dried over sodium sulfate, filtered, and
evaporated to afford a crude product as a light brown sticky solid.
The crude material was purified by column chromatography (ethyl
acetate/hexane as solvent system) to afford
N-(4,4-difluorocyclohexyl)-6-(1-ethoxyvinyl)-2-(4-methylthiazol-2-yl)pyri-
midin-4-amine (4.1 g, 10.78 mmol, 75%) as an off-white solid. MS
(MH+): m/z=381.0.
[0065] Step 2:
##STR00018##
[0066] A round-bottomed flask equipped with a teflon-coated stir
bar was charged with
N-(4,4-difluorocyclohexyl)-6-(1-ethoxyvinyl)-2-(4-methylthiazol-2-yl)pyri-
midin-4-amine (9.0 g, 23.67 mmol, 1.0 eq) in acetone (120 mL)
followed by addition of 2N hydrochloric acid aqueous solution (20
mL). The reaction mixture was stirred at room temperature for 3
hours and completion of reaction was determined by LCMS. The
reaction mixture was concentrated to remove acetone, diluted with
ice cold water (100 mL), basified with saturated sodium by
carbonate solution, and extracted with ethyl acetate (2.times.100
mL). The combined organics were dried over sodium sulfate,
filtered, and evaporated under reduced pressure to afford a crude
product as a light brown sticky solid. The crude material was
purified by column chromatography (ethyl acetate/hexane as solvent
system) to afford
1464(4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidin-4-yl-
)ethan-1-one (6.1 g, 17.32 mmol, 73%) as an off-white solid. MS
(MH+): m/z=353.0.
[0067] Step 3:
##STR00019##
[0068] A round-bottomed flask equipped with a teflon-coated stir
bar was charged with
1-(6(4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidin-4-yl-
)ethan-1-one (5.6 g, 15.90 mmol, 1.0 eq) in methanol (80 mL) at
-10.degree. C. followed by sodium borohydride (0.302 g, 7.95 mmol,
0.5 eq). The reaction mixture was stirred at same temperature for 1
hour and completion of reaction was determined by LCMS. The
reaction mixture was quenched with water and concentrated under
reduced pressure to remove methanol. The residue was diluted with
ice cold water (100 mL) and extracted with ethyl acetate
(2.times.100 mL). The combined organics were dried over sodium
sulfate, filtered, and evaporated under reduced pressure to afford
1-(6(4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidin-4-yl-
)ethan-1-ol 4 (5.5 g, 15.53 mmol, 97%) as an off-white solid of
racemic mixture. MS (MH+): m/z=355.0.
[0069] Step 4:
##STR00020##
[0070] The racemic compound
1-(6-((4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidin-4--
yl)ethan-1-ol 4 (5.5 g) was purified by chiral HPLC (Column:
Chiralpak-IC (250*20*5.0 .mu.); Mobile phase-A:N-Hexane (0.1% DEA),
Mobile phase-B: IPA:DCM(90:10) isocratic: 50:50 (A:B); Flow rate:
15.0 ml/min; 120/inj; Run time: 15 min) to afford
(S)-1-(6-((4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidi-
n-4-yl)ethan-1-ol 5 (2.1 g, 5.93 mmol, 38%) as an off-white solid
from first eluting fractions (Peak-1, RT=4.24 min.). MS (MH+):
m/z=355.0. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.59-7.57
(d, J=6.0 Hz, 1H), 7.37(s, 1H), 6.64 (s, 1H), 5.37-5.36 (d, J=4.4
Hz, 1H), 4.52-4.50 (t, J=11.2 Hz, 5.6 Hz, 1H), 4.05 (bs, 1H), 2.43
(s, 3H), 2.10-1.96 (m, 6H), 1.62-1.59 (m, 2H), 1.35-1.33 (d, J=6.4
Hz, 3H). Other enantiomer:
(R)-1-(6-((4,4-difluorocyclohexyl)amino)-2-(4-methylthiazol-2-yl)pyrimidi-
n-4-yl)ethan-1-ol 6 (2.05 g, 5.78 mmol, 37%) as an off-white solid
from second eluting fractions (Peak-2, RT=6.45 min.). MS (MH+):
m/z=355.0. .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 6 7.60-7.59
(d, J=5.6 Hz, 1H), 7.37(s, 1H), 6.64 (s, 1H), 5.38 (bs, 1H),
4.52-4.51 (d, J=6.8 Hz, 1H), 4.10 (bs, 1H), 2.43 (s, 3H), 2.10-1.91
(m, 6H), 1.65-1.57 (m, 2H), 1.35-1.34 (d, J=6.8 Hz, 3H).
2-(3-cyclopropyl-1H-pyrazol-1-yl)-N-(4,4-difluorocyclohexyl)-6-morpholinop-
yrimidin-4-amine
[0071] Step 1:
##STR00021##
[0072] A 1000-mL three-necked, flame-dried, round-bottomed flask,
equipped with a teflon-coated stir bar (3 cm), one septa (neck 1),
stopper (neck 3) and reflux condenser equipped with nitrogen gas
inlet-outlet U-tube adaptor filled with oil (Neck 2), was charged
with a solution of 4,6-dichloro-2-(methylthio)pyrimidine (150 g,
768.94 mmol, 1.0 equiv.) in acetonitrile (1500 mL) followed by
4,4-difluorocyclohexylamine hydrochloride (158.35 g, 922.733 mmol)
and cesium carbonate (526 g, 1614 mmol, 2.1 equiv.). The reaction
mixture was heated at 75.degree. C. for 16 h. The reaction mixture
was filtered to remove cesium carbonate, then the filtrate was
concentrated under reduced pressure to afford 210 g (93% yield) of
6-chloro-N-(4,4-difluorocyclohexyl)-2-(methylthio)pyrimidin-4-a-
mine as a pale yellow solid. MS (MH+): m/z=294.0.
[0073] Step 2:
##STR00022##
[0074] A solution of 6-chloro-N-(4,
4-difluorocyclohexyl)-2-(methylthio)pyrimidin-4-amine (60 g, 204.24
mmol, 1.0 equiv.) and morpholine (35.6 mL, 408.48 mmol, 2.0 equiv.)
in acetonitrile (600 mL) was heated at 85.degree. C. in a sealed
tube for 16 h. After completion of the reaction, the reaction
mixture was concentrated, and the resulting residue was quenched
with ice cold water. The obtained solid was filtered and washed
with water (500 mL), hexane (250 mL), dried under high vacuum to
afford
N-(4,4-difluorocyclohexyl)-2-(methylthio)-6-morpholinopyrimidin-4-amine
as an off-white solid (62 g, 88% yield). MS (MH+): m/z=345.2.
[0075] Step 3:
##STR00023##
[0076] A 100-mL three-necked, flame-dried, round-bottomed flask,
equipped with a teflon-coated stir bar (3 cm), one septa (neck 1),
stopper (neck 3) and reflux condenser equipped with nitrogen gas
inlet-outlet U-tube adaptor filled with oil (Neck 2), was charged
with a solution of
N-(4,4-difluorocyclohexyl)-2-(methylthio)-6-morpholino
pyrimidin-4-amine (1g, 2.90 mmol) in tetrahydrofuran (15 mL)
followed by 4-N,N-dimethylaminopyridine (0.1 g, 0.87 mmol, 0.3
equiv.), triethylamine (1.2 mL, 8.71 mmol, 3.0 equiv.) and Boc
anhydride (3.16 g, 14.51 mmol, 5.0 equiv.) then the reaction
mixture was heated at 80.degree. C. for 16 h. After completion of
the reaction, the reaction mixture was quenched with water and
extracted with ethyl acetate (2.times.75 mL). The combined organic
layer was dried over anhydrous sodium sulfate and concentrated to
afford tert-butyl (4,4-difluorocyclohexyl)(2-(methylthi
o)-6-morpholino pyrimidin-4-yl)carbamate as a yellow gum (1.1 g,
85%). MS (MH+): m/z=445.2.
[0077] Step 4:
##STR00024##
[0078] A 100-mL single neck round bottom flask, connected with
reflux condenser equipped with nitrogen gas inlet-outlet U-tube
adaptor filled with oil, a teflon-coated stir bar (1 cm), was
charged with a solution of tert-butyl
(4,4-difluorocyclohexyl)(2-(methylthio)-6-morpholinopyrimidin-4-yl)carbam-
ate (50 g, 112.47 mmol) in dichloromethane (600 mL) followed by
3-chloroperbenzoic acid (m-chloroperbenzoic acid) (58.2 g, 337.42
mmol, 3.0 equiv.) at 0.degree. C. The reaction mixture was slowly
warmed to rt and stirred for 30 min. After the completion of the
reaction, the reaction mixture was quenched with saturated
bicarbonate solution and extracted with dichloromethane
(2.times.250mL). The combined organic layer was dried over
anhydrous sodium sulfate and concentrated to afford tert-butyl
(4,4-difluorocyclohexyl)(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)ca-
rbamate as an off-white gum (52 g, 97% yield). MS (MH+): m/z
=477.3.
[0079] Step 5:
##STR00025##
[0080] A 100-mL single neck round bottom flask, connected with
reflux condenser equipped with nitrogen gas inlet-outlet U-tube
adaptor filled with oil, a teflon-coated stir bar (2 cm), was
charged with a solution of tert-butyl
(4,4-difluorocyclohexyl)(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)ca-
rbamate (0.9 g, 1.88 mmol) in acetonitrile (10 mL) followed by
3-cyclopropyl-1H-pyrazole (0.3 g, 2.83 mmol, 1.5 equiv.) and cesium
carbonate (1.23 g, 3.77 mmol, 2.0 equiv.). The reaction mixture was
heated at 80.degree. C. for 16 hours, and completion of reaction
was determined by TLC and LCMS. The reaction mixture was filtered
and the filtrate was concentrated. The crude product was purified
through column chromatography using 60-120 silica gel with ethyl
acetate-pet ether as solvent system. The isolated material was
dried under vacuum to afford tert-butyl
(2-(3-cyclopropyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-yl)(4,4-difluo-
rocyclohexyl)carbamate as an off-white solid (0.8 g, 84%). MS
(MH+): m/z=505.
[0081] Step 6:
##STR00026##
[0082] A 100-mL three-necked, flame-dried, round-bottomed flask,
equipped with a teflon-coated stir bar (2 cm), one septa (necks 1),
stopper (neck 3) and nitrogen gas inlet-outlet U-tube adaptor
filled with oil (Neck 2), was charged with a solution tert-butyl
(2-(3-cyclopropyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-yl)(4,4-difluo-
rocyclohexyl)carbamate (1.2 g, 1.98 mmol, 1 eq) in dichloromethane
(40 mL) followed by trifluoroacetic acid (2.5 mL, 32.55 mmol, 16.4
eq) at 0.degree. C. The reaction mixture was slowly warmed to rt
and stirred at same temperature for 6 hours. The completion of
reaction was determined by TLC and UPLC. The reaction mixture was
concentrated and the resulting residue was quenched with 10%
saturated sodium bicarbonate solution, extracted with ethyl acetate
(2.times.100 mL), and concentrated under reduced pressure to afford
crude product. The crude product was purified through column
chromatography using 60-120 silica gel, ethyl acetate-pet ether as
solvent system. The resulting solid was dried under vacuum to
afford
2-(3-cyclopropyl-1H-pyrazol-1-yl)-N-(4,4-difluorocyclohexyl)-6-mor-
pholinopyrimidin-4-amine 7 (0.73g, 90%). MS (MH+): m/z=405.
Analytical Data: .sup.1H-NMR (400 MHz, DMSO-d.sub.6): .delta. 8.39
(d, J=2.4 Hz, 1H), 7.08 (d, J=8.0 Hz, 1H), 6.14 (d, J=2.80 Hz, 1
H), 5.53 (s, 1H), 3.88 (s, 1H), 3.69-3.67 (m, 4H), 3.50 (m, 4H),
1.99-1.90 (m, 7H), 1.56-1.54 (m, 2H), 0.93-0.89 (m, 2H), 0.72-0.71
(m, 2H).
BIOLOGICAL ASSAYS
[0083] The biological activity was determined as follows. The ionic
current through small-conductance Ca.sup.2+-activated K.sup.+
channels (SK channels, subtype 2) was measured using the whole-cell
configuration of the patch-clamp technique in a patch-clamp set-up
using HEK293 tissue culture cells expressing SK2 channels as
described in Hougaard et al., British Journal of Pharmacology 151,
655-665, May 8, 2007, the entire teachings of which are
incorporated herein by reference. In one aspect, a compound is
defined to be an SK Positive Allosteric Modulator (PAM) if the
compound increases current in this assay, for example, if the
SC.sub.100 value of the compound is less than or equal to 10 .mu.M
as determined by this assay. The SC.sub.100 value is defined to be
the concentration of compound that increases the basal current by
100%.
[0084] The SC.sub.100 value is given in Table 1.
[0085] Male Sprague Dawley rats were administered with either
Vehicle, 10, or 30 mg/Kg Compound 1 by oral administration 30
minutes prior to harmaline injection to investigate the therapeutic
effect of Compound 1 on harmaline induced tremor. Immediately
following harmaline injection, animals were placed in the tremor
quantification apparatus and tremor events were quantified for 60
minutes. A tremor event signal was generated when a small metal
transmitter band fitted to the right forepaw of the animal moved
within the electromagnetic field generated by a loop antenna within
the testing apparatus. Outputs from the amplifier were digitized at
a sampling rate of 1,000 Hz and the signal was processed and
analyzed using LabView software (National Instruments). To minimize
signal from ambulatory and grooming behavior, the signal was
filtered with a 128-ms unweighted moving average filter, and events
with amplitudes >0.5 V and lasting >300 ms in duration were
counted as a tremor event. Data were analyzed in one-minute bins
over the course of the test and presented as the sum of tremor
events over the entire 60 minute test. As shown by FIG. 1,
significant inhibition of tremors was observed at a dose of 30
mg/Kg Compound 1.
[0086] Reduction of tremor with Compound 1 has also been
demonstrated by measurement of whole-body tremor frequency via a
force-plate accelerometer.
[0087] Whole body tremor was measured by a San Diego Instruments
Tremor Monitor (San Diego, Calif., USA). Animals were pre-treated
with 3, 10, or 30 mg/kg Compound 1 orally 30 minutes prior to
intraperitoneal administration of 5 mg/kg harmaline. Tremor was
measured for 30 minutes following harmaline administration, and
data were analyzed by fast Fourier transform and reported as a
frequency power spectrum. Harmaline induced a significant increase
in the power spectrum in a band of frequencies between 10 and 14
Hz. In this range, 3, 10, and 30 mg/kg all significantly reduced
tremor. Data were further analyzed by calculating the percent
Motion Power (% MP), defined as the power in the 9-13 Hz band
divided by the total power across the spectrum (0-30 Hz) multiplied
by 100. By this analysis, 3, 10, and 30 mg/kg significantly reduced
harmaline-induced tremor (harmaline+vehicle (n=13); harmaline+3
mg/kg Compound 1 (n=8), P<0.01; 10 mg/kg Compound 1 (n=16) and
30 mg/kg Compound 1 (n=13), respectively, P<0.05) (FIG. 2).
[0088] Taken together, these data show that Compound 1
significantly reduces harmaline-induced tremor measured by two
different experimental designs.
[0089] The extent to which compounds modulate SK2 channels in vivo
is expressed as % SK2 SC.sub.100, which is the ratio of the
concentration of the drug free in the brain to the measured potency
of the compound on the SK2 channel. It is calculated as follows:
C.sub.FB=C.sub.MB.times.BFF, where C.sub.MB is the concentration of
compound measured by liquid chromatography mass spectrometry from
brains harvested immediately following tremor recording (Table 1,
"Measured Brain Concentration"). CFB is the amount of free compound
not complexed with protein and therefore free to interact with the
SK2 channel (Table 1, "Calculated Free Brain Concentration"). BFF
is average free fraction of compound as measured by equilibrium
dialysis in separate experiments (1 uM test concentration incubated
in 10% rat brain tissue homogenate for 5 hours at 37.degree. C.)
(Table 1, "Brain Free Fraction"). Free drug in brain available to
interact with SK2 channels (Cm) is arrived at by multiplying the
measured total brain level (Cm) by the average free fraction
(BFF).
[0090] The amount of free compound is then expressed in terms of
its potency against the SK2 channel as follows: % SK2
SC.sub.100=C.sub.FB/SK2 SC.sub.100.times.100, where SK2 SC.sub.100
(Table 1, "SK2 SC.sub.100") is the measured value of potency of the
compound on SK2 channels and % SK2 SC100 (Table 1, "% SK2
SC.sub.100") is the free brain concentration (C.sub.FB) normalized
to SK2 SC.sub.100. Values are given in Table 1.
TABLE-US-00001 TABLE 1 Minimally Measured Calculated Efficacious
Brain Measured Free Brain Measured Dose Concentration Brain Free
Concentration SK2 SC.sub.100 Calculated % Compound (mg/Kg) (.mu.M)
Fraction (.mu.M) (.mu.M) SK2 SC.sub.100 1 30 1.3 0.065 0.08 0.5
16
Effect on Purkinje Cell Firing Irregularity in Ex Vivo Slices from
SCA2 58Q Transgenic Mice
[0091] In cerebellar slices from SCA2 58Q mice, Purkinje neurons
exhibit chaotic firing, measurable as an increase in the
coefficient of variation of the interspike interval (ISI CV), a
measure of the regularity of the firing interval between action
potentials. The difference in ISI CV between wild-type (N=8) and
SCA2 58Q (N=11) mice is illustrated in FIG. 3 (P<0.005). Also
shown, sequential bath application of 1 (N=11) or 3 .mu.M (N=10)
Compound 1 partially reversed the increase in ISI CV observed in
cerebellar slices from eleven-month old SCA2 58Q mice (P<0.05).
These data indicate that Compound 1 regularizes Purkinje firing by
partially restoring the interspike interval in this mouse model of
Spinocerebellar Ataxia.
Evaluation of Compound Effect in Episodic Ataxia 2 (EA2) Tottering
Mouse Model
[0092] Compound 1 has demonstrated efficacy in validated animal
models of hereditary ataxia (EA2) and ET (harmaline-induced
tremor). To test whether Compound 1 can alleviate ataxia in a
disease model, it was evaluated in the EA2 "Tottering" mouse model.
These mice display a basal ataxia that arises from irregularity in
Purkinje cell pacemaker firing due to a loss-of-function mutation
in P/Q Ca.sup.2+ channels (the same protein that is mutated in
SCA6), which causes Episodic Ataxia 2 (EA2). Animals were assessed
in the parallel rod floor apparatus which automatically counts the
number of times the animal's foot slips through the evenly spaced
metal rods and the total distance the animal travels. Baseline
ataxia was then expressed as the Ataxia Ratio, which is the total
number of foot slips divided by the total distance the animal
travels in centimeters. The increase in Ataxia Ratio between
wild-type and EA2 mice is illustrated in FIG. 4.
[0093] In this study, EA2 (8-10 months old; n=18) mice were
injected intraperitoneally with Compound 1 or vehicle 30 minutes
prior to being placed in the parallel rod floor apparatus. Animals
were assessed in a cross-over study design with each animal
receiving both vehicle and 10 mg/kg Compound 1. Three days were
allowed between doses for washout of the compound. At the dose
administered in this study, Compound 1 fully reversed the increase
in Ataxia Ratio observed in EA2 vs wild-type mice. These data
indicate that Compound 1 restores normal performance in this
measure of motor function in a model of hereditary cerebellar
ataxia.
Comparative Advantages
[0094] The following studies illustrate further technical
advantages of the compounds disclosed herein.
[0095] Aqueous solubility (kinetic solubility) tests of the
compounds were performed in phosphate buffer saline (pH 7.4)
measured by shake-flask method. In this assay, DMSO stock solution
of test compound is added to buffer followed by equilibration
(shaking), filtration and determination of soluble amount by
HPLC-UV Conditions used in the assay are summarized below. Results
are shown in Table 2 and Table 3. [0096] Compound concentration:
200 .mu.M with 1% DMSO (n=2) [0097] Aqueous buffer: 0.05M Phosphate
Buffer System pH 7.4 [0098] Equilibration period: 16 hours at room
temperature (-23.degree. C.) with agitation [0099] Sample
preparation: Filtration [0100] Analysis: HPLC-UV [0101] Reference
compounds: Caffeine (high solubility) and Diethylstilbestrol (low
solubility)
[0102] Metabolic stability profiling of the compounds was performed
in liver microsomes. In this assay, test compound is incubated with
liver microsomes in the presence of NADPH for 2 time points at
37.degree. C. At the end of incubation, reaction is quenched with
acetonitrile containing internal standard and the parent compound
remaining is determined by LC-MS/MS. Conditions used in the assay
are summarized below. Results are shown in Table 2. [0103]
Incubation time: 0 and 30 minutes at pH 7.4, 37.degree. C. [0104]
Test concentration: 1 .mu.M in 0.02% DMSO at pH 7.4 (n=2) [0105]
NADPH concentration in assay: 1 mM [0106] Liver microsome protein
concentration in assay: 0.5 mg/ml [0107] Analysis: LC-MS/MS [0108]
Data reported: % Parent Compound Remaining (% PCR) [0109] Reference
compounds for high and low clearance are included [0110] Species
tested: mouse, rat, dog, monkey, and human
[0111] Compounds described herein were tested for CYP inhibition
across 5 isoforms (3A4, 2D6, 2C9, 2C19 & 1A2). In this assay,
CYP isoform specific substrates are incubated with human liver
microsome (HLM) in the presence of test compounds, and metabolite
formation is determined. Percentage inhibition of metabolite
formation at different concentrations of test compound is
calculated and IC50 is determined. Conditions used in the assay are
summarized below. Results are shown in Table 2. [0112] Test drug
(Inhibitor) Concentration: 8 different concentrations (100 .mu.M to
0.005 .mu.M) [0113] Matrix: Human Liver Microsome (Invitrogen, life
technologies) [0114] Specific probe substrates will be used for the
isoforms as given below: [0115] CYP3A4: Midazolam [0116] CYP2D6:
Bufuralol [0117] CYP2C9: Diclofenac [0118] CYP2C19: Mephynitoin
[0119] CYP1A2: Phenacetin [0120] Cofactors: NADPH (1 mM final in
assay) [0121] Sample Analysis: LC-MS/MS (metabolites) [0122]
Specific reference inhibitors included in all assays
(Ketoconazole/Quinidine/Sulphaphenazole/Ticlopidine/Furafylline)
[0123] Buffer: Potassium Phosphate Buffer (100 mM) pH 7.4 [0124]
DMSO level in assay: 0.1% [0125] Data analysis: % Inhibition over
control
[0126] Compounds were tested in a cardiac potassium channel hERG
assay. hERG is responsible for a rapid delayed rectifier current
(I.sub.Kr) in human ventricles. Inhibition of I.sub.Kr is the most
common cause of cardiac action potential prolongation by
non-cardiac drugs. See e.g., Brown, A.M. and Rampe, D. (2000).
Drug-induced long QT syndrome: is HERG the root of all evil?
Pharmaceutical News 7, 15-20.
[0127] HEK-293 cells were stably transfected with hERG cDNA. Stable
transfectants were selected by coexpression with the
G418-resistance gene incorporated into the expression plasmid.
Selection pressure was maintained by including G418 in the culture
medium. Cells were cultured in Dulbecco's Modified Eagle
Medium/Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10%
fetal bovine serum, 100 U/mL penicillin G sodium, 100 .mu.g/mL
streptomycin sulfate and 500 .mu.g/mL G418. Cell culture records
are kept on file at Charles River Laboratories.
[0128] Cells were transferred to the recording chamber and
superfused with vehicle control solution. Pipette solution for
whole cell recordings was (composition in mM): potassium aspartate,
130; MgCl.sub.2, 5; EGTA, 5; ATP, 4; HEPES, 10; pH adjusted to 7.2
with KOH. Pipette solution was prepared in batches, aliquoted,
stored frozen, and a fresh aliquot thawed each day. Patch pipettes
were made from glass capillary tubing using a P-97 micropipette
puller (Sutter Instruments, Novato, Calif.). A commercial patch
clamp amplifier was used for whole cell recordings. Before
digitization, current records were low-pass filtered at one-fifth
of the sampling frequency.
[0129] Onset and steady state inhibition of hERG current was
measured using a pulse pattern with fixed amplitudes (conditioning
prepulse: +20 mV for 2 s; test pulse: -50 mV for 2 s) repeated at
10 s intervals, from a holding potential of -80 mV. Peak tail
current was measured during the 2 s step to -50 mV.
[0130] One test article concentration was applied to each cell
(n=3). Peak current was measured during the test ramp. A steady
state was maintained for at least 30 seconds before applying test
article or positive control. Peak current was measured until a new
steady state was achieved. Results are shown in Table 2.
[0131] Oral bioavailability data was collected in rat as follows.
Results are shown in Table 2. [0132] Rat strain/sex: Sprague
Dawley/Male [0133] Age/body weight: 6 to 8 weeks/250-300 gms [0134]
No of animals per group: n=3 [0135] Total no of groups: 2 (1 mpk IV
& 10 mpk PO) [0136] Route of administration: Oral
(PO)/Intravenous (IV) [0137] Dosing volume: Intravenous (2 ml/kg)
& Oral (10 ml/kg) [0138] Formulation vehicles: Standard
formulations or suggested by Sponsor Dose levels (IV & Oral): 1
mg/kg; intravenous & 10 mg/kg; oral or as suggested [0139]
Fast/Fed: Oral dosing will be performed with overnight fasted
animal Dosing frequency: Single dose [0140] Time points for blood
collection: (57 plasma samples for analysis) [0141] IV--10 points
(pre-dose; 5min; 15 min; 30 min; 1 h; 2 h; 4 h; 6 h; 8 h; 24 h)
[n=3 rats] [0142] PO--9 points (pre-dose; 15 min; 30 min; 1 h; 2 h;
4 h; 6 h; 8 h; 24 h) [n=3 rats] [0143] Blood samples collection:
Jugular vein cannula [0144] Anti-coagulant: 0.2% K2 EDTA [0145]
Sample analysis by discovery grade bioanalytical method developed
for estimation of test compound in plasma using LC-MS/MS
systems.
TABLE-US-00002 [0145] TABLE 2 ##STR00027## ##STR00028##
##STR00029## SK2 potency 400 nM 1380 nM 5800 nM (SC.sub.100).sup.a
Brain Free 6.1% 1.2% NA Fraction.sup.a Kinetic solubility 0.074
0.017 NA (mg/mL) Liver Mouse 47% 1% NA microsome Rat 60% 1% NA
stability.sup..dagger. Dog 54% 2% NA Monkey 46% 1% NA Human 84% 50%
NA Cyp1A2 >10 uM 640 nM NA inhibition (IC.sub.50) Cyp3A4 >10
uM >10 uM NA inhibition (IC.sub.50) Cyp2D6 >10 uM 790 nM NA
inhibition (IC.sub.50) hERG >10 uM >10 uM NA inhibition
(IC.sub.50) Oral bio- 81% 5% NA availability.sup..sctn. SC.sub.100
= Concentration that produces doubling of channel current
.sup.aSmall discrepancy in number when compared with prior table
due to insignificant differences in averages taken from later
experiments. .sup..dagger.% remaining at 1 hour .sup..sctn.10 mg/kg
PO, 0.5 mg/kg IV in rat
[0146] As shown by the data in Table 2 above, Compound 1 is over
3-fold more potent on SK2 then Comparator A and over 14-fold more
potent on SK2 then Comparator B. Compound 1 also has better
solubility, higher BFF, higher microsomal stability, and greater
oral bioavailability than Comparator A. An overall improvement in
BFF and solubility over Comparator A and phenyl derivative
Comparator C was also demonstrated across the compounds described
herein as shown in Table 3. Compound 1 is reproduced from above for
ease of comparison.
TABLE-US-00003 TABLE 3 Brain Kinetic Free solubility Fraction
(mg/mL) ##STR00030## 0.16% 0.001 ##STR00031## 6.1% 0.074
##STR00032## 2.76% 0.031 ##STR00033## 2.69% 0.0709 ##STR00034##
4.20% 0.0803 ##STR00035## 4.31% 0.0667 ##STR00036## 1.55%
0.0497
[0147] While we have described a number of embodiments of this
invention, it is apparent that our basic examples may be altered to
provide other embodiments that utilize the compounds and methods of
this invention. Therefore, it will be appreciated that the scope of
this invention is to be defined by the appended claims rather than
by the specific embodiments that have been represented by way of
example.
[0148] The contents of all references (including literature
references, issued patents, published patent applications, and
co-pending patent applications) cited throughout this application
are hereby expressly incorporated herein in their entireties by
reference. Unless otherwise defined, all technical and scientific
terms used herein are accorded the meaning commonly known to one
with ordinary skill in the art.
* * * * *